The LPCAT1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from Raji human B lymphocytes. This loss-of-function model targets the LPCAT1 gene, encoding lysophosphatidylcholine acyltransferase 1, to enable studies of phospholipid metabolism and its roles in lymphocyte function. The polyclonal format ensures broad genetic representation while achieving functional ablation of LPCAT1 activity, facilitating robust phenotypic analyses.
Raji is an EBV-positive Burkitt’s lymphoma cell line widely used to investigate B-cell malignancies, immune surveillance, and antibody production. As a B lymphocyte model, it expresses surface immunoglobulins and engages in antigen presentation, providing a tractable system for examining signal transduction pathways that regulate proliferation, apoptosis, and drug resistance.
LPCAT1 operates in the Lands cycle, catalyzing the conversion of lysophosphatidylcholine to phosphatidylcholine, the major membrane phospholipid, and also acetylates lyso-platelet-activating factor to form PAF. Its expression is governed by nuclear receptors (PPARs, LXR), SREBP1, cAMP signaling, and inflammatory mediators (TNF??, IL-1??). The enzyme utilizes acyl-CoA and CoA, and collaborates with LPCAT2, LPCAT3, PLA2, AGPAT, and DGAT in glycerophospholipid metabolism. Knockout of LPCAT1 disrupts phosphatidylcholine biosynthesis and PAF production, altering membrane composition and impacting lipid-dependent signaling.
In Raji B cells, LPCAT1 deficiency perturbs phosphatidylcholine homeostasis, likely compromising membrane integrity, B-cell receptor (BCR) clustering, and survival signaling. This disruption may render the lymphoma cells more susceptible to apoptosis, affect drug transporter function, or impair lipid raft organization, offering a platform to dissect metabolic dependencies in B-cell lymphomas and explore links between lipid metabolism and oncogenesis.
These polyclonal knockout cells support diverse experimental workflows, including LC-MS-based phospholipid profiling, MTS proliferation assays, Annexin V apoptosis detection, RT-qPCR and Western blot confirmation of LPCAT1 gene disruption, flow cytometry of B-cell surface markers, and PAF quantification. Applications span cancer metabolism, lipidomics, BCR signaling, drug resistance, and surfactant biology, with disease relevance to Burkitt’s lymphoma, lung adenocarcinoma, breast cancer, glioma, asthma, and pulmonary fibrosis. For additional information, please contact Ascent Research.
